A study of a triple-combination inhaler for COPD
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new inhaler that combines three medicines (fluticasone, formoterol, and glycopyrronium) to see if it helps people with chronic obstructive pulmonary disease (COPD) breathe better and have fewer flare-ups. It may be an option if you have COPD and are looking for a convenient once- or twice-daily treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older.
- You have a diagnosis of COPD confirmed by a breathing test (spirometry) showing a low FEV1/FVC ratio.
- You are not pregnant or breastfeeding.
- You do not currently have asthma (though a past history of asthma is okay as long as COPD is your main diagnosis).
- You do not have other serious lung diseases like tuberculosis, sarcoidosis, or pulmonary fibrosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
This study tests a new inhaled powder medicine (TQC3927) against an existing combination inhaler for treating COPD, a lung disease that makes breathing difficult. The goal is to see if the new medicine works as well or better and is safe for people with COPD.
This study looks at how well a triple-combination inhaler called Breztri/Trixeo works for people with moderate to severe COPD. If you have been prescribed this inhaler but haven't started it yet, and you are between 30 and 80 years old, you may be able to join.
This study tests a new injectable medicine called CM310 for people with moderate to severe COPD who have chronic bronchitis and frequent flare-ups, despite using standard inhalers. It aims to see if CM310 can reduce flare-ups and improve breathing by targeting a specific type of inflammation.
This study looks at how well a triple inhaler (BDP/FF/GB) works for people with severe COPD in Brazil. It may help those who have had at least one flare-up in the past year.
This study tests a fixed triple combination inhaler (Trimbow) for people whose asthma is not well controlled with their current treatment. It looks at how well this inhaler works in everyday life over time.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.